p.96 抽出テキスト

Heart J Qual Care Clin Outcomes 2025;11:197–205. https://doi.org/10. 1093/ehjqcco/qcae095 517. Sankaranarayanan R, Rasoul D, Murphy N, Kelly A, Nyjo S, Jackson C, et al. Telehealth-aided outpatient management of acute heart failure in a specialist virtual ward compared with standard care. ESC Heart Fail 2024;11:4172–84. https://doi.org/10.1002/ehf2.15003 518. Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail 2016;4:1–8. https://doi.org/10.1016/j.jchf.2015.06.017 519. Keshvani N, Rizvi S, Segar MW, Miller JW, Coellar JD, Patel KV, et al. Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: a pilot randomized controlled trial. Eur J Heart Fail 2025;27:347–52. https://doi.org/10.1002/ ejhf.3537 520. Konstam MA, Massaro J, Dhingra R, Walsh M, Ordway L, Pursley MS, et al. Avoiding treatment in hospital with subcutaneous furosemide for worsening heart failure: a pilot study (AT HOME-HF). JACC Heart Fail 2024;12: 1830–41. https://doi.org/10.1016/j.jchf.2024.07.015 521. Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail 2018;6:65–70. https://doi.org/10.1016/j.jchf. 2017.10.001 522. Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J 2023;44:2966–77. https://doi.org/10.1093/eurheartj/ehad341 523. Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT, Adams K, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 2024;83:1295–306. https://doi.org/10.1016/j.jacc.2024. 02.009 524. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 2022;146: 289–98. https://doi.org/10.1161/CIRCULATIONAHA.122.059038 525. Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, et al. Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium–glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. Circulation 2025. https://doi.org/10.1161/CIRCULATIONAHA.125. 076575 526. Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. J Am Coll Cardiol 2024;83:1386–98. https://doi.org/10.1016/ j.jacc.2024.02.020 527. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296–304. https://doi.org/10.1056/ NEJMoa1210357 528. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675–83. https://doi.org/10.1016/j.jacc.2006.07.073 529. Chioncel O, Mebazaa A, Farmakis D, Abdelhamid M, Lund LH, Harjola VP, et al. Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2025;27:1067–88. https://doi.org/10.1002/ejhf.3673 530. Patel PA, Heizer G, O’Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail 2014;7:918–25. https://doi.org/10.1161/CIRCHEARTFAILURE.113. 000872 531. Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 2017;376:1956–64. https://doi.org/10.1056/NEJMoa1601895 532. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, et al. Effects of serelaxin in patients with acute heart failure. N Engl J Med 2019; 381:716–26. https://doi.org/10.1056/NEJMoa1801291 533. Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA 2019;322:2292–302. https://doi.org/10.1001/jama.2019.18598 534. Lukoschewitz JD, Miger KC, Olesen ASO, Caidi NOE, Jorgensen CK, Nielsen OW, et al. Vasodilators for acute heart failure—a systematic review with meta-analysis. NEJM Evid 2024;3:EVIDoa2300335. https://doi.org/10. 1056/EVIDoa2300335 535. Riccardi M, Pagnesi M, Chioncel O, Mebazaa A, Cotter G, Gustafsson F, et al. Medical therapy of cardiogenic shock: contemporary use of inotropes and vasopressors. Eur J Heart Fail 2024;26:411–31. https://doi.org/10.1002/ ejhf.3162 536. Uhlig K, Efremov L, Tongers J, Frantz S, Mikolajczyk R, Sedding D, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2020; 11:CD009669. https://doi.org/10.1002/14651858.CD009669.pub4 537. Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med 2021;385:516–25. https://doi.org/10.1056/ NEJMoa2026845 538. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779–89. https://doi.org/10.1056/NEJMoa0907118 539. Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2018;72:173–82. https://doi.org/10. 1016/j.jacc.2018.04.051 540. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 2005;294:3124–30. https://doi.org/10. 1001/jama.294.24.3124 541. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020; 22:713–22. https://doi.org/10.1002/ejhf.1713 542. Dominguez-Rodriguez A, Suero-Mendez C, Burillo-Putze G, Gil V, Calvo-Rodriguez R, Pinera-Salmeron P, et al. Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial. Eur J Heart Fail 2022;24:1953–62. https://doi. org/10.1002/ejhf.2602 543. Lorusso R, Salazar L, Nersesian G, Milojevic M, Schmack B, Engelman DT, et al. EACTS expert consensus document on protected cardiac surgery: preemptive use of temporary mechanical circulatory support in adult cardiac surgery patients at high risk for perioperative low cardiac output syndrome. Eur J Cardiothorac Surg 2025;68:ezaf296. https://doi.org/10.1093/ejcts/ ezaf296 544. Potapov EV, Whitman G, John R, Lanmuller P, Tucanova Z, Arora RC, et al. EACTS/STS/AATS Guidelines on temporary mechanical circulatory support in adult cardiac surgery. Eur J Cardiothorac Surg 2025. https://doi.org/10. 1093/ejcts/ezaf330 545. Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 concise clinical guidance: an ACC expert consensus statement on the evaluation and management of cardiogenic shock: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;85: 1618–41. https://doi.org/10.1016/j.jacc.2025.02.018 546. Thiele H, Moller JE, Henriques JPS, Bogerd M, Seyfarth M, Burkhoff D, et al. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up. Lancet 2024;404:1019–28. https://doi.org/10.1016/ S0140-6736(24)01448-X 547. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2020;323:734–45. https://doi.org/10.1001/jama.2020.0254 548. Thiele H, Jobs A, Ouweneel DM, Henriques JPS, Seyfarth M, Desch S, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017;38:3523–31. https://doi.org/10.1093/eurheartj/ ehx363 549. Moller JE, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, Polzin A, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 2024;390:1382–93. https://doi.org/10. 1056/NEJMoa2312572 550. Moller JE, Beske RP, Engstrom T, Jensen LO, Eiskjaer H, Mangner N, et al. Long-term outcomes of the DanGer Shock trial. N Engl J Med 2025;393: 1037–8. https://doi.org/10.1056/NEJMc2508284 551. Lusebrink E, Binzenhofer L, Thiele H. The DanGer Shock trial: a new dawn but much to uncover. Eur Heart J 2024;45:4181–3. https://doi.org/10.1093/ eurheartj/ehae516 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026